Addex Therapeutics operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Addex Therapeutics with three other
pharmaceutical manufacturers in Europe:
sales of 23.20 million Danish Kroner [US$3.78 million]
of which 58%
was The NGAL test),
(1.78 million Euros [US$2.15 million]
of which 61%
was Oncology products), and
Isofol Medical AB (publ)
based in SWEDEN
(37.12 million Swedish Kronor [US$4.46 million]
During the first
quarter of 2021, sales at Addex Therapeutics totalled
922,421.00 Swiss Francs.
This is a drop of 3.2%
from the 952,456.00 Swiss Francs in sales at the company during the first quarter in 2020.
Addex Therapeutics reported sales of 3.88 million Swiss Francs (US$4.31 million)
December of 2020.
increase of 36.9%
versus 2019, when the company's sales were 2.83 million Swiss Francs.
Despite this increase, sales are still
below the level achieved in 2018, when Addex Therapeutics
reported sales of 6.70 million Swiss Francs.